S&P 500   3,286.23 (-0.72%)
DOW   26,520.25 (-0.52%)
QQQ   272.06 (-1.57%)
AAPL   109.22 (-5.29%)
MSFT   203.12 (-0.78%)
FB   269.28 (-4.11%)
GOOGL   1,647.26 (+5.81%)
AMZN   3,089.70 (-3.78%)
TSLA   397.26 (-3.30%)
NVDA   510.49 (-2.01%)
BABA   309.08 (-1.11%)
CGC   18.58 (-1.06%)
GE   7.36 (-0.14%)
MU   49.90 (-1.15%)
AMD   75.84 (-2.79%)
T   26.79 (+0.11%)
F   7.78 (-1.52%)
ACB   3.95 (-3.42%)
GILD   58.06 (-0.80%)
NIO   30.36 (-5.10%)
NFLX   494.00 (-2.02%)
BA   146.63 (-1.12%)
DIS   120.75 (-0.65%)
S&P 500   3,286.23 (-0.72%)
DOW   26,520.25 (-0.52%)
QQQ   272.06 (-1.57%)
AAPL   109.22 (-5.29%)
MSFT   203.12 (-0.78%)
FB   269.28 (-4.11%)
GOOGL   1,647.26 (+5.81%)
AMZN   3,089.70 (-3.78%)
TSLA   397.26 (-3.30%)
NVDA   510.49 (-2.01%)
BABA   309.08 (-1.11%)
CGC   18.58 (-1.06%)
GE   7.36 (-0.14%)
MU   49.90 (-1.15%)
AMD   75.84 (-2.79%)
T   26.79 (+0.11%)
F   7.78 (-1.52%)
ACB   3.95 (-3.42%)
GILD   58.06 (-0.80%)
NIO   30.36 (-5.10%)
NFLX   494.00 (-2.02%)
BA   146.63 (-1.12%)
DIS   120.75 (-0.65%)
S&P 500   3,286.23 (-0.72%)
DOW   26,520.25 (-0.52%)
QQQ   272.06 (-1.57%)
AAPL   109.22 (-5.29%)
MSFT   203.12 (-0.78%)
FB   269.28 (-4.11%)
GOOGL   1,647.26 (+5.81%)
AMZN   3,089.70 (-3.78%)
TSLA   397.26 (-3.30%)
NVDA   510.49 (-2.01%)
BABA   309.08 (-1.11%)
CGC   18.58 (-1.06%)
GE   7.36 (-0.14%)
MU   49.90 (-1.15%)
AMD   75.84 (-2.79%)
T   26.79 (+0.11%)
F   7.78 (-1.52%)
ACB   3.95 (-3.42%)
GILD   58.06 (-0.80%)
NIO   30.36 (-5.10%)
NFLX   494.00 (-2.02%)
BA   146.63 (-1.12%)
DIS   120.75 (-0.65%)
S&P 500   3,286.23 (-0.72%)
DOW   26,520.25 (-0.52%)
QQQ   272.06 (-1.57%)
AAPL   109.22 (-5.29%)
MSFT   203.12 (-0.78%)
FB   269.28 (-4.11%)
GOOGL   1,647.26 (+5.81%)
AMZN   3,089.70 (-3.78%)
TSLA   397.26 (-3.30%)
NVDA   510.49 (-2.01%)
BABA   309.08 (-1.11%)
CGC   18.58 (-1.06%)
GE   7.36 (-0.14%)
MU   49.90 (-1.15%)
AMD   75.84 (-2.79%)
T   26.79 (+0.11%)
F   7.78 (-1.52%)
ACB   3.95 (-3.42%)
GILD   58.06 (-0.80%)
NIO   30.36 (-5.10%)
NFLX   494.00 (-2.02%)
BA   146.63 (-1.12%)
DIS   120.75 (-0.65%)
Log in
NASDAQ:TCRR

Tcr2 Therapeutics Price Target, Predictions & Analyst Ratings

Top-Rated Stocks  
$19.25
-0.30 (-1.53 %)
(As of 10/30/2020 09:40 AM ET)
Add
Compare
Today's Range
$19.25
Now: $19.25▼
$19.66
50-Day Range
$18.00
MA: $19.91▼
$22.28
52-Week Range
$5.84
Now: $19.25▼
$22.84
Volume202 shs
Average Volume191,624 shs
Market Capitalization$641.87 million
P/E RatioN/A
Dividend YieldN/A
Beta1.89

Analyst Ratings

Tcr2 Therapeutics (NASDAQ:TCRR) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Tcr2 Therapeutics in the last 12 months. Their average twelve-month price target is $31.80, predicting that the stock has a possible upside of 65.19%. The high price target for TCRR is $35.00 and the low price target for TCRR is $25.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
TCRR Consensus Rating: BuyBuyBuyBuy
TCRR Consensus Rating Score: 3.003.003.002.75
TCRR Analyst Ratings: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)		0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)		0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)		0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
TCRR Consensus Price Target: $31.80$31.80$33.33$17.50
TCRR Price Target Upside: 65.19% upside107.49% upside130.63% upside12.71% upside

Tcr2 Therapeutics (NASDAQ:TCRR) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Tcr2 Therapeutics (NASDAQ:TCRR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/20/2020MizuhoInitiated CoverageBuyMedium
8/13/2020HC WainwrightLower Price TargetBuy$33.00 ➝ $32.00High
8/12/2020Truist FinancialInitiated CoverageBuyHigh
8/12/2020SVB LeerinkLower Price TargetOutperform$26.00 ➝ $25.00High
8/12/2020Piper SandlerInitiated CoverageOverweight$35.00Low
7/27/2020Roth CapitalUpgradeNeutral ➝ Buy$16.00 ➝ $35.00High
7/27/2020WedbushBoost Price TargetOutperform$25.00 ➝ $32.00High
3/11/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$31.00High
3/11/2019BMO Capital MarketsInitiated CoverageOutperform$37.00High
(Data available from 10/30/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 10/30/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.